Auricular Vagus Stimulation and STEMI
NCT: NCT05992259 · COMPLETED
Brief Summary
At the moment, the invasive strategy for the infarct-associated coronary artery in patients with ST-segment elevation myocardial infarction (STEMI) necessary to save the myocardium and reduce the size of the necrosis zone remains the leading one. However, despite the high efficiency of providing medical care to patients with acute coronary syndrome (ACS), there remains a high mortality and disability of this group of patients. In this regard, the search for new drug and non-drug strategies for the treatment of patients with ACS is actively continuing. Over the past decade, it has been shown that transcutaneous vagus nerve stimulation (TENS) has a cardioprotective effect both in chronic heart failure and in coronary heart disease, improves cardiac function, prevents reperfusion injury, weakens myocardial remodeling, increases the effectiveness of defibrillation and reduces the size of a heart attack. One of the methods of noninvasive stimulation of the afferent fibers of the vagus nerve is percutaneous electrical stimulation of the auricular branch of the vagus nerve. However, further studies are needed to determine whether stimulation of the tragus can improve the long-term clinical outcome in this cohort of patients.
Frequently Asked Questions
What is Auricular Vagus Stimulation and STEMI?
Auricular Vagus Stimulation and STEMI is a clinical trial registered under NCT05992259. Current status: COMPLETED.
What is the status of NCT05992259?
The current status of NCT05992259 (Auricular Vagus Stimulation and STEMI) is: COMPLETED.
When did Auricular Vagus Stimulation and STEMI start?
Auricular Vagus Stimulation and STEMI started on 2022-09-01.
Related Devices
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.